CSIMarket Company Name, Ticker, Industry, else..
 
Verona Pharma Plc  (NASDAQ: VRNA)
 

Verona Pharma Plc's Suppliers Performance

VRNA's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
VRNA Costs vs Sales of Suppliers Growth

• More on VRNA Suppliers






Verona Pharma Plc's Comment on Supply Chain


The company manufactures ensifentrine and drug delivery devices, such as nebulizers, for clinical trials using raw materials sourced from contract manufacturing organizations (CMOs) and third-party suppliers. Delays or shortages from these CMOs or suppliers could significantly impact clinical trials, product testing, regulatory approval, and commercial sales of ensifentrine. The company may need to identify alternative suppliers to prevent disruptions. Additionally, cost increases and labor constraints at CMOs could affect manufacturing and delivery timelines. The company also relies on CMOs and suppliers to respect proprietary rights; any infringement issues could necessitate finding alternatives or defending claims, potentially affecting the development and marketing of ensifentrine.

Verona Pharma Plc's Comment on Supply Chain


The company manufactures ensifentrine and drug delivery devices, such as nebulizers, for clinical trials using raw materials sourced from contract manufacturing organizations (CMOs) and third-party suppliers. Delays or shortages from these CMOs or suppliers could significantly impact clinical trials, product testing, regulatory approval, and commercial sales of ensifentrine. The company may need to identify alternative suppliers to prevent disruptions. Additionally, cost increases and labor constraints at CMOs could affect manufacturing and delivery timelines. The company also relies on CMOs and suppliers to respect proprietary rights; any infringement issues could necessitate finding alternatives or defending claims, potentially affecting the development and marketing of ensifentrine.







VRNA's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Verona Pharma Plc 9,718.43 221.67 -81.19 79
SUBTOTAL 0.00 0.00 0.00 -


Sources: Verona Pharma Plc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Verona Pharma Plc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.